Livmarli Patient Counseling Information

Advise the patient or their caregiver(s) to read the Patient Information and Instructions for Use.
Administration Instructions: Advise patients or their caregivers(s) to: Take LIVMARLI 30 minutes prior to a meal in the morning using a calibrated measuring device (0.5 mL, 1 mL or 3 mL oral dispenser) to measure and deliver the prescribed dose accurately [see Dosing and Important Administration Instructions under Dosage & Administration].
Take LIVMARLI at least 4 hours before or 4 hours after taking a bile acid binding resin (e.g., cholestyramine, colesevelam, or colestipol) [see Effects of Other Drugs on LIVMARLI under Interactions].
Store the opened bottle below 30°C. Discard any unused LIVMARLI 100 days after opening the bottle [see Storage].
Liver Test Abnormalities: Advise patients or their caregiver(s) that liver tests should be obtained before starting LIVMARLI and periodically during LIVMARLI therapy, due to the risk of elevation in liver tests and development of liver-related adverse reactions [see Dose Modification for Management of Adverse Events under Dosage & Administration; Liver Test Abnormalities under Precautions].
Gastrointestinal Adverse Reactions: Advise patients or their caregiver(s) to notify their healthcare provider if they experience new onset or worsening of gastrointestinal symptoms [see Gastrointestinal Adverse Reactions under Precautions].
Fat Soluble Vitamin (FSV) Deficiency: Advise patients or their caregiver(s) that INR (for vitamin K) and serum levels of vitamins A, D, E will be obtained before starting and periodically during treatment to assess for FSV deficiency [see Fat Soluble Vitamin (FSV) Deficiency under Precautions].